CINECA IRIS Institutional Research Information System

SICCARDI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.703
EU - Europa 3.066
AS - Asia 746
AF - Africa 36
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 5
Totale 8.576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.684
DK - Danimarca 1.045
CN - Cina 433
DE - Germania 333
IT - Italia 271
SE - Svezia 242
IE - Irlanda 239
FR - Francia 181
GB - Regno Unito 170
UA - Ucraina 164
FI - Finlandia 161
KR - Corea 125
AT - Austria 109
SG - Singapore 74
PL - Polonia 70
IN - India 35
NL - Olanda 29
VN - Vietnam 28
ZA - Sudafrica 28
CA - Canada 18
BE - Belgio 17
EU - Europa 9
TW - Taiwan 8
JP - Giappone 7
UZ - Uzbekistan 7
ID - Indonesia 6
IR - Iran 6
TH - Thailandia 6
BR - Brasile 5
CZ - Repubblica Ceca 4
ES - Italia 4
PT - Portogallo 4
RU - Federazione Russa 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
HR - Croazia 3
NO - Norvegia 3
PK - Pakistan 3
AR - Argentina 2
GH - Ghana 2
IL - Israele 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PY - Paraguay 2
BD - Bangladesh 1
CO - Colombia 1
CU - Cuba 1
EE - Estonia 1
HK - Hong Kong 1
HU - Ungheria 1
IM - Isola di Man 1
KE - Kenya 1
LI - Liechtenstein 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TR - Turchia 1
VE - Venezuela 1
Totale 8.576
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.015
Chandler 424
Beijing 344
Dublin 239
Fairfield 164
Houston 147
Dearborn 143
Villeurbanne 137
Ashburn 130
Wilmington 126
Jacksonville 125
Princeton 106
Torino 105
Vienna 105
Medford 99
Nyköping 97
Seattle 83
Woodbridge 71
Warsaw 70
Cambridge 46
Redwood City 46
Fremont 43
Singapore 42
New York 38
Boardman 26
Milan 24
Pisa 24
Munich 23
Boston 17
Verona 17
Brussels 16
Dong Ket 14
Toronto 14
Falls Church 13
Kunming 11
Amsterdam 10
Nürnberg 10
Cape Town 9
Guangzhou 9
Hefei 9
Helsinki 8
Norwalk 8
Alberton 7
Edinburgh 7
Shanghai 7
Washington 7
Des Moines 6
Isfahan 6
Los Angeles 6
Pune 6
Indianapolis 5
Jakarta 5
Kharkiv 5
Rome 5
San Diego 5
Taipei 5
Turin 5
Brno 4
Hangzhou 4
Jinan 4
London 4
Mountain View 4
Nanjing 4
Phoenix 4
Pretoria 4
Silver Spring 4
Wuhan 4
Chengdu 3
Goodwood 3
Leawood 3
Nanchang 3
Piemonte 3
Redmond 3
Tirupati 3
Zhongxin 3
Accra 2
Asunción 2
Atlanta 2
Bangalore 2
Baotou 2
Burlington 2
Changsha 2
Copenhagen 2
Costa Mesa 2
Dallas 2
Frankfurt am Main 2
Fuzhou 2
Goiânia 2
Göteborg 2
Hadera 2
Hamburg 2
Leiden 2
Naples 2
Oslo 2
Paris 2
Philadelphia 2
San Jose 2
San Mateo 2
Shenyang 2
Stockholm 2
Totale 5.408
Salva come PNG Salva come JPEG
Nome #
Ceftriaxone bone penetration in patients with septic non-union of the tibia 289
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 275
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 248
Raltegravir penetration in seminal plasma of healthy volunteers. 247
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 236
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 234
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 229
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 229
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 175
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 171
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 171
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 170
Effect of multidrug-resistant gene polymorphisms on daptomycin concentrations: preliminary results 162
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 161
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 161
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 160
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 157
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 153
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 153
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 152
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 151
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 150
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 148
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia 147
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 146
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 145
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 143
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 143
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 142
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 141
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 140
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 138
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 137
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 136
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 134
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 130
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T 129
Is Maraviroc a substrate for SLCO1B1? 128
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 128
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 93
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir 83
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. 82
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 78
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 74
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 71
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) 70
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 70
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir 69
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance 69
Class-specific relative genetic contribution for key antiretroviral drugs 69
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 67
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens 64
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV 64
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon 63
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method 61
A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting 59
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient 59
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 59
Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor. 58
PHARMACOKINETICS AND PHARMACOGENETICS OF MARAVIROC IN THE CLINICAL SETTING 53
Solute Carrier Organic Anion Transporter 1B1 (SLCO1B1) Mediates Transport of Maraviroc Using a X. leavis Model 52
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. 51
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients 51
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene 49
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. 47
PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING 47
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. 38
Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels 36
Intracellular Accumulation of Tipranavir/Ritonavir 36
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. 31
Intracellular Pharmacokinetics of ATV/RTV Is Influenced by Solute Carrier Organic Anion Transporter 3A1 Expression 31
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. 29
Totale 9.017
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.587
article - articoli 0
book - libri 0
conference - conferenze 10.607
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.194
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.951 33 19 37 126 253 393 162 54 76 177 278 343
2020/2021990 265 31 21 55 52 46 60 23 78 80 49 230
2021/20222.229 228 191 227 240 178 191 244 212 139 59 158 162
2022/20231.256 133 50 20 110 152 334 86 98 138 16 83 36
2023/2024467 53 77 28 28 42 82 6 34 5 15 31 66
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 9.017